poisar

Stock

Karyopharm Therapeutics Inc. KPTI

$1.99+0.04%

Overview

KPTI market data

Price History

KPTI price chart

Valuation & Profitability

Provider-backed
P/E (TTM)
Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
Forward P/E
P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
EPS (TTM)
-$17.93
Diluted earnings per share over the trailing twelve months.
Beta
0.98
Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
Dividend Yield
Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
Profit Margin
-129.0%
Net income divided by revenue. Comparable within a sector, less so across sectors.
52w range
$1.80 – $10.99
Lowest and highest closing prices over the past 52 weeks.
Analyst Target
Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.

Display-only. Refreshed once per symbol per 24 hours · market cap $46M · P/B 22.52 · P/S 0.30.

Company News

10 captured
Karyopharm Therapeutics Reports Q2 2026 Results: Full Earnings Call TranscriptBenzinga · Aug 13, 2026, 12:54 PM
8-K filing — Karyopharm Therapeutics Inc. (KPTI)SEC EDGAR · Aug 13, 2026, 11:37 AM
Karyopharm Therapeutics Affirms FY2026 Sales Guidance of $130.000M-$150.000M vs $133.736M EstBenzinga · Aug 13, 2026, 11:32 AM
Karyopharm Therapeutics Q2 EPS $(2.32) Misses $(1.28) Estimate, Sales $33.432M Beat $32.188M EstimateBenzinga · Aug 13, 2026, 11:31 AM
Karyopharm Therapeutics shares are trading lower after the company announced topline results from its Phase 3 XPORT-EC-042 trial did not meet its primary endpoint of progression free survival. Also, Piper Sandler lowered its price target on the stock from $16 to $7.Benzinga · Jul 31, 2026, 4:46 PM
Crude Oil Gains 1%; Apple Shares Tumble After Q3 ResultsBenzinga · Jul 31, 2026, 4:02 PM
Piper Sandler Maintains Overweight on Karyopharm Therapeutics, Lowers Price Target to $7Benzinga · Jul 31, 2026, 2:49 PM
Nasdaq Surges 300 Points; Amazon Shares Jump Following Upbeat EarningsBenzinga · Jul 31, 2026, 1:44 PM
This Faeth Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For FridayBenzinga · Jul 31, 2026, 1:11 PM
Amazon To Rally Around 55%? Here Are 10 Top Analyst Forecasts For FridayBenzinga · Jul 31, 2026, 12:14 PM

Decision & Score

Members

Our Tradable / Watch / Avoid decision and 0–100 conviction score for this symbol are members-only.

Create account to unlock

Trend & Pattern Evidence

Members

Trend alignment and backtested chart-pattern probabilities are members-only.

Create account to unlock

Sector Peer Ranking

Members

Ranked sector peers with scores and decisions are members-only.

Create account to unlock